References
- Clements M, Berry G, Shi J, Ware S, Yates D, Johnson A. Projected mesothelioma incidence in men in New South Wales. Occup Environ Med 2007; 64:747–52.
- Chua TC, Yan TD, Morris DL. Peritoneal mesothelioma: Current understanding and management. Can J Surg 2009; 52:59–64.
- Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, . Current treatment options and biology of peritoneal mesothelioma: Meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol 2006; 17:1615–9.
- Carteni G, Manegold C, Martin Garcia G, Siena S, Zielinski CC, Amadori D, . Malignant peritoneal mesothelioma – Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009; 64:211–8.
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636–44.
- Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, . Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: Final report of a phase II trial. J Clin Oncol 2008; 26:3567–72.
- Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, . Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173:1155–60.
- Park EK, Sandrini A, Yates D, Creaney J, Robinson BW, Thomas PS, . Soluble mesothelin-realted protein in an Asbetos-exposed population. Am J Respir Crit Care Med 2008; 178:832–7.
- Fasola G, Puglisi F, Follador A, Aita M, Di Terlizzi S, Belvedere O. Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: A case report. BMC Cancer 2006; 6:289–
- Miliauskas S, Zemaitis M, Pranys D. Malignant pleural and peritoneal mesothelioma: Incidental diagnosis and excellent treatment results. J Thor Oncol 2009; 4:435–6.